Zacks Investment Research upgraded shares of Strongbridge Biopharma (NASDAQ:SBBP) from a hold rating to a buy rating in a research report sent to investors on Tuesday morning, Zacks.com reports. They currently have $3.50 price objective on the biotechnology company’s stock.
According to Zacks, “Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing’s syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. “
Several other research firms also recently commented on SBBP. BidaskClub raised Zumiez from a hold rating to a buy rating in a research note on Friday, April 26th. TheStreet cut YRC Worldwide from a c rating to a d+ rating in a research report on Wednesday, May 15th. ValuEngine cut Zosano Pharma from a buy rating to a hold rating in a research report on Wednesday, May 1st. Finally, Oppenheimer set a $15.00 target price on Strongbridge Biopharma and gave the stock a buy rating in a research report on Tuesday, March 26th. Two equities research analysts have rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $13.07.
Strongbridge Biopharma (NASDAQ:SBBP) last posted its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported ($0.34) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.09. The firm had revenue of $4.34 million during the quarter, compared to the consensus estimate of $4.69 million. Strongbridge Biopharma had a return on equity of 79.31% and a net margin of 227.79%. On average, equities research analysts predict that Strongbridge Biopharma will post -1.36 EPS for the current year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in SBBP. Stonebridge Capital Management Inc. acquired a new stake in shares of Strongbridge Biopharma in the 1st quarter worth approximately $55,000. Stifel Financial Corp acquired a new stake in shares of Strongbridge Biopharma in the 4th quarter worth approximately $73,000. Oppenheimer & Co. Inc. grew its holdings in shares of Strongbridge Biopharma by 90.8% in the 1st quarter. Oppenheimer & Co. Inc. now owns 45,448 shares of the biotechnology company’s stock worth $226,000 after acquiring an additional 21,626 shares during the period. Private Advisors LLC acquired a new stake in shares of Strongbridge Biopharma in the 1st quarter worth approximately $263,000. Finally, Tibra Equities Europe Ltd acquired a new stake in shares of Strongbridge Biopharma in the 1st quarter worth approximately $324,000. Institutional investors and hedge funds own 50.12% of the company’s stock.
About Strongbridge Biopharma
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency.
Featured Story: How prevalent are 12b-1 fees?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.